Health AI Central
Peer-Reviewed Publication
Clin Pharmacol Ther2026;120(5):1157-1162.November 1, 2026Editorial

New Approach Methodologies (NAMs): Guiding Clinical Predictions through Human-Relevant Evidence.

Aarzoo Thakur1, Eric Chun Yong Chan2, Mohamed Elmeliegy3, Karen Rowland Yeo4
1Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
2Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, Singapore, Singapore.
3Pfizer, Inc., San Diego, California, USA.
4Certara UK Limited, (Simcyp Division), Sheffield, UK.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.